Hans P Schwarz

Summary

Affiliation: Baxter Healthcare Corporation
Country: USA

Publications

  1. ncbi request reprint Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease
    H P Schwarz
    Baxter Hyland Immuno, Vienna, Austria
    Wien Klin Wochenschr 111:181-91. 1999
  2. ncbi request reprint The 1st International Standard for von Willebrand Factor concentrate: more to come?
    Hans P Schwarz
    Baxter BioScience, Vienna, Austria
    Thromb Haemost 88:376-7. 2002
  3. ncbi request reprint Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model
    Simone Schatz
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Br J Haematol 123:692-5. 2003
  4. ncbi request reprint Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease
    H P Schwarz
    Hyland Immuno Division, Baxter Healthcare, Vienna, Austria
    Haemophilia 4:53-62. 1998
  5. ncbi request reprint Karl Landsteiner and his major contributions to haematology
    Hans Peter Schwarz
    Baxter BioScience, Vienna, Austria
    Br J Haematol 121:556-65. 2003
  6. ncbi request reprint Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease
    Hans Peter Schwarz
    Baxter BioScience, Vienna, Austria
    Semin Thromb Hemost 28:215-26. 2002
  7. ncbi request reprint Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice
    H P Schwarz
    Baxter Hyland Immuno and University of Vienna, Vienna, Austria
    Blood 95:1703-8. 2000
  8. ncbi request reprint Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein
    Simone M Schatz
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Br J Haematol 125:629-37. 2004
  9. ncbi request reprint Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII
    Christina Hausl
    Center for BioMolecular Therapeutics, Vienna, Austria
    Thromb Haemost 87:840-5. 2002
  10. ncbi request reprint Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell-surface layers
    Dirk Völkel
    Baxter BioScience, Vienna, Austria
    Transfusion 43:1677-82. 2003

Collaborators

  • P L Turecek
  • F Scheiflinger
  • B M Reipert
  • P J Lenting
  • Markus Glatzel
  • Jan Voorberg
  • P Noel Barrett
  • Martin Spruth
  • Miha Furlan
  • Thomas R Kreil
  • P H Reitsma
  • Christina Hausl
  • Friedrich Dorner
  • Rafi U Ahmad
  • Klaus Zimmermann
  • Elisabeth Maier
  • Maria Sasgary
  • Dirk Völkel
  • Katharina Pfistershammer
  • Wendy S Bril
  • Daniel Kolarich
  • Eva M Muchitsch
  • Christian Fiedler
  • Simone M Schatz
  • Herbert Gritsch
  • Günter Richter
  • Simone Schatz
  • Randolf Kerschbaumer
  • Barbara Plaimauer
  • Michèle Himmelspach
  • Tina Novy-Weiland
  • Willfried Auer
  • Bernhard Baumgartner
  • Leopold Grillberger
  • Koen Mertens
  • Alfred Weber
  • Jürgen Siekmann
  • Karin Fijnvandraat
  • Martine J Hollestelle
  • Marleen G Zuurveld
  • Peter Matthiessen
  • Rene A W van Lier
  • Gerry A F Nicolaes
  • Friedrich Altmann
  • Artur Mitterer
  • Michael Graninger
  • Johannes Stockl
  • Pauline M W van Helden
  • Christopher B Doering
  • Pete Lollar
  • Michael Dockal
  • Meinhard Hasslacher
  • Andreas Breitwieser
  • Margit Sara
  • Sabrina Pable
  • Uwe B Sleytr
  • Bernhard Lammle
  • Uwe Schlokat
  • Evelyn Muhr
  • Katalin Varadi
  • Helen Gerritsen
  • Pegah Jenab
  • Gerhard Antoine

Detail Information

Publications25

  1. ncbi request reprint Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease
    H P Schwarz
    Baxter Hyland Immuno, Vienna, Austria
    Wien Klin Wochenschr 111:181-91. 1999
    ..Although no effect was seen on bleeding time at the dosages used, the rate of blood flow from cuticle wounds was reduced after a single bolus administration of rvWF. The rvWF was able to control a severe nose bleed in one dog...
  2. ncbi request reprint The 1st International Standard for von Willebrand Factor concentrate: more to come?
    Hans P Schwarz
    Baxter BioScience, Vienna, Austria
    Thromb Haemost 88:376-7. 2002
  3. ncbi request reprint Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model
    Simone Schatz
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Br J Haematol 123:692-5. 2003
    ..While in vitro experiments showed that the chimaeric molecules had higher haemostatic functions than the wild-type proteins, the variables analysed in vivo were similar for both proteins...
  4. ncbi request reprint Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease
    H P Schwarz
    Hyland Immuno Division, Baxter Healthcare, Vienna, Austria
    Haemophilia 4:53-62. 1998
    ..Although no effect was seen on bleeding time at the dosages used, the rate of blood flow from cuticle wounds was reduced after a single bolus administration of rvWF. The rvWF was able to control a severe nose bleed in one dog...
  5. ncbi request reprint Karl Landsteiner and his major contributions to haematology
    Hans Peter Schwarz
    Baxter BioScience, Vienna, Austria
    Br J Haematol 121:556-65. 2003
  6. ncbi request reprint Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease
    Hans Peter Schwarz
    Baxter BioScience, Vienna, Austria
    Semin Thromb Hemost 28:215-26. 2002
    ..Administration of the receptor-associated protein (RAP) as a recombinant fusion protein to vWF knockout mice significantly improved the in vivo recovery of recombinant FVIII and the survival time of otherwise rapidly cleared FVIII...
  7. ncbi request reprint Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice
    H P Schwarz
    Baxter Hyland Immuno and University of Vienna, Vienna, Austria
    Blood 95:1703-8. 2000
    ..These findings suggest that the accelerated clearance of factor VIII seen in the absence of vWF may be a result of the involvement of LRP in factor VIII metabolism. (Blood. 2000;95:1703-1708)..
  8. ncbi request reprint Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein
    Simone M Schatz
    Baxter BioScience, Biomedical Research Centre, Orth Donau, Austria
    Br J Haematol 125:629-37. 2004
    ..The W2313A mutation weakens binding to phosphatidyl-l-serine vesicles but the mutant protein has the same effector function as dBFVIII in vitro and in vivo...
  9. ncbi request reprint Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII
    Christina Hausl
    Center for BioMolecular Therapeutics, Vienna, Austria
    Thromb Haemost 87:840-5. 2002
    ..The IgG-subclass distribution of anti-FVIII ASC was similar in spleen and bone marrow and matched the subclasses of anti-FVIII antibodies in blood plasma indicating that both organs contribute to circulating antibodies in the blood...
  10. ncbi request reprint Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell-surface layers
    Dirk Völkel
    Baxter BioScience, Vienna, Austria
    Transfusion 43:1677-82. 2003
    ..The pathologic protein is detected by Western blot analysis or ELISA methods. The bovine spongiform encephalopathy crisis and occurrence of a new variant of CJD has increased demand for rapid and simple assays...
  11. ncbi request reprint Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives
    Thomas R Kreil
    Global Pathogen Safety, Operations Central Europe, R and D Biopharmaceuticals, and R and D Vaccines, Baxter BioScience, Vienna, Austria
    Transfusion 46:1143-51. 2006
    ....
  12. ncbi request reprint Update on the mechanism of action and future of activated prothrombin complex concentrates
    Peter L Turecek
    Baxter BioScience, Industriestrasse 67, A 1220 Vienna, Austria
    Curr Hematol Rep 3:331-7. 2004
    ....
  13. ncbi request reprint Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells
    Katharina Pfistershammer
    BMT Research, Vienna, Austria
    Thromb Haemost 96:309-16. 2006
    ..We conclude that neither of these proteins present danger signals to human DCs...
  14. ncbi request reprint Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy
    Daniel Kolarich
    University of Natural Resources and Applied Life Sciences, Vienna, Austria
    Transfusion 46:1959-77. 2006
    ..The protein, including glycoproteomic analyses, and structural features of A1PI products were investigated by state-of-the-art techniques...
  15. ncbi request reprint Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders
    Christina Hausl
    Biomedical Therapeutics Research, Vienna, Austria
    Blood 104:115-22. 2004
    ..As expected, the production of anti-FVIII antibodies by plasma cells is not dependent on any of the costimulatory interactions tested...
  16. ncbi request reprint In vivo and in vitro processing of recombinant pro-von Willebrand factor
    Peter L Turecek
    Baxter BioScience, Industriestrasse 67, 1220 Vienna, Austria
    Histochem Cell Biol 117:123-9. 2002
    ..Hirudin preconditioning of vWF-deficient mice attenuated processing of infused recombinant pro-vWF suggesting that thrombin plays a part in the processing events in vivo...
  17. ncbi request reprint Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor
    Peter L Turecek
    Baxter BioScience, Vienna, Austria
    Semin Thromb Hemost 28:149-60. 2002
    ..The CBA method appears not only to be more sensitive and easier to carry out than the RCo method is but also to have a higher reproducibility and allow better standardization...
  18. ncbi request reprint A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo
    Michèle Himmelspach
    Baxter BioScience, Vienna, Austria
    Thromb Haemost 88:1003-11. 2002
    ..In the Wessler test, rfII/rfXa showed no thrombogenicity. These data show that a well-defined, particularly safe and efficacious agent with fVIII bypassing activity can be generated from recombinant fII and fXa...
  19. ncbi request reprint Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)
    Barbara Plaimauer
    Baxter BioScience, Biomedical Research Center, Orth, Austria
    Blood 100:3626-32. 2002
    ..These data show that ADAMTS13 is responsible for the physiologic proteolytic degradation of VWF multimers...
  20. ncbi request reprint Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII
    Maria Sasgary
    Baxter BioScience, Vienna, Austria
    Thromb Haemost 87:266-72. 2002
    ..In a few experiments IL-4-producing T cells were seen but in most experiments they were not detectable. In contrast, IL-4 could be found in supernatants of in vitro restimulated CD8- spleen cells...
  21. ncbi request reprint TT virus does not contaminate first-generation recombinant factor VIII concentrate
    Thomas R Kreil
    Blood 100:2271-2; author reply 2272. 2002
  22. ncbi request reprint Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution
    Wendy S Bril
    Department of Plasma Proteins, Sanquin Research at CLB, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    Thromb Haemost 95:341-7. 2006
    ..These results indicate that huFVIII-R593C/E-16KO mice are tolerant to intravenously administered factor VIII. It is anticipated that this model may prove useful for studying immune responses in the context of factor VIII gene therapy...
  23. pmc High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors
    Christina Hausl
    Biomolecular Therapeutics GmbH BMT Research, Vienna, Austria
    Blood 106:3415-22. 2005
    ..We conclude that the inhibition of FVIII-specific memory B cells might be an early event in the down-modulation of anti-FVIII antibodies in patients with hemophilia A who receive high doses of FVIII...
  24. ncbi request reprint A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions
    Birgit M Reipert
    Thromb Haemost 89:1110-2; author reply 1113. 2003
  25. ncbi request reprint Induction of immune tolerance by oral IVIG
    Elisabeth Maier
    Baxter AG, Vienna, Austria
    Int Immunopharmacol 7:351-9. 2007
    ..These data give promising indications that oral human IgG might represent an alternative approach for immunosuppressive B-cell targeted therapies in RA...